APPLICATION
ANDA218383
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
ABACAVIR; DOLUTEGRAVIR; LAMIVUDINENone (Tentative Approval)
ABACAVIR 30MG, DOLUTEGRAVIR, LAMIVUDINE · TABLET · ORAL
ABACAVIR; DOLUTEGRAVIR; LAMIVUDINENone (Tentative Approval)
ABACAVIR 60MG, DOLUTEGRAVIR, LAMIVUDINE · TABLET · ORAL
ABACAVIR; DOLUTEGRAVIR; LAMIVUDINENone (Tentative Approval)
ABACAVIR 5MG, DOLUTEGRAVIR, LAMIVUDINE · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.